Ther­a­cos­Bio aims to chal­lenge Big Phar­ma block­busters with new­ly-ap­proved SGLT2 for di­a­betes

Ther­a­cos­Bio is squar­ing up for its lit­tle-en­gine-that-could mo­ment. Its type 2 di­a­betes med Bren­zavvy nabbed FDA ap­proval on Fri­day, land­ing the pri­vate­ly-fund­ed, lit­tle-known biotech in a big are­na al­ready pop­u­lat­ed by Big Phar­ma play­ers.

John­son & John­son’s In­vokana, As­traZeneca’s Farx­i­ga, and Boehringer In­gel­heim and Eli Lil­ly’s co-mar­ket­ed Jar­diance are long-es­tab­lished SGLT2 in­hibitors. In­vokana was first ap­proved in 2013, fol­lowed by Jar­diance and As­traZeneca in 2014, giv­ing them a head start of al­most a decade on Bren­zavvy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER